Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to B-cell Acute Lymphoblastic Leukemia
Related studies linked through entity extraction aliases.
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
- Status
- RECRUITING
- Phase
- PHASE2
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
CAR T Cell Therapy Related Cardiovascular Outcomes
- Status
- COMPLETED
- Phase
- N/A
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Status
- RECRUITING
- Phase
- PHASE2
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Venetoclax Plus Inotuzumab for B-ALL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Induced-T Cell Like NK Cells for B Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
- Status
- RECRUITING
- Phase
- PHASE2
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Blinatumomab Bridging Therapy for BALL
- Status
- TERMINATED
- Phase
- PHASE2
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2